North America In-Vitro Diagnostics Market Forecast to 2030 – Regional Analysis – by Product & Services (Reagents & Kits, Instruments, and Software & Services), Technology (Immunoassay/ Immunochemistry, Clinical Chemistry, Molecular Diagnostics, Microbiolo

North America In-Vitro Diagnostics Market Forecast to 2030 – Regional Analysis – by Product & Services (Reagents & Kits, Instruments, and Software & Services), Technology (Immunoassay/ Immunochemistry, Clinical Chemistry, Molecular Diagnostics, Microbiology, Blood Glucose Self-Monitoring, Coagulation & Hemostasis, Hematology, Urinalysis, and Others), Application (Infectious Diseases, Diabetes, Oncology, Cardiology, Autoimmune Diseases, Nephrology, and Others), and End User (Hospitals, Laboratories, Homecare, and Others)

The North America in-vitro diagnostics market is expected to grow from US$ 21,207.07 million in 2022 to US$ 33,183.41 million by 2030. It is estimated to grow at a CAGR of 5.8% from 2022 to 2030.

Growth in Point-of-Care Testing and Surge in Demand for IVD during COVID-19 Pandemic Fuels North America In-Vitro Diagnostics Market

Point-of-care testing (POCT) is a pivotal opportunity in the in vitro diagnostics market, revolutionizing healthcare delivery with its potable and rapid diagnostic capabilities. These tests, conducted at or near the patient’s location, offer immediate results, enabling timely clinical decision-making. Several factors drive the growth of POCT.

Firstly, the demand for convenient and swift diagnostic solutions in healthcare settings, such as emergency rooms, clinics, and home care, propels the expansion of POCT. Secondly, technological advancements have led to the development of compact and user-friendly POCT devices.

Moreover, the COVID-19 pandemic underscored the significance of rapid and accessible diagnostics. The pandemic accelerated the deployment and utilization of point-of-care COVID-19 tests, showcasing the relevance and potential of POCT in managing infectious diseases on a global scale. This experience accelerated research and development on POCT, further driving innovation and investment in portable testing solutions.

IVDs that are used in the diagnosis of infectious diseases include immunoassays, and molecular assays. Diagnostics companies also focus on making rapid advancements in their offerings to manage COVID-19. Further, regulatory authorities introduced temporary amendments or modifications to their standards, which favored the launches of new IVDs during the pandemic. The demand for molecular diagnostics and immunoassays surged due to these government initiatives. Thus, the COVID-19 pandemic has benefitted the in-vitro diagnostics market due to the rising demand for point-of-care (POC) diagnostics and laboratory testing procedures.

North America In-Vitro Diagnostics Market Overview

North America region includes the US, Canada, and Mexico. It holds the largest share of the in-vitro diagnostics market by geography. All three countries in the region are witnessing considerable demand for in-vitro diagnostics. Certain factors, such as the increasing prevalence of chronic & infectious diseases, focus on efficient disease diagnosis, and a higher need for advanced healthcare systems are boosting the adoption of in-vitro diagnostics in the region. The US held the largest share of the North America in-vitro diagnostics market. Chronic diseases such as cancer and cardiovascular diseases are the major causes of disability and death in the US. Per the National Center for Chronic Disease Prevention and Health Promotion, 6 in 10 people in the country have at least one chronic disease. According to the Centers for Disease Control and Prevention (CDC), in 2021, ~18.2 million adults aged 20 and above had coronary artery disease (CAD) in the US. Heart disease is the leading cause of death among people in the country. Additionally, the American Hospital Association estimates ~133 million people have at least one chronic disease, and that number is expected to reach 170 million by 2030. The high incidence of chronic diseases results in a huge demand for diagnostic procedures, which, in turn, drives the in-vitro diagnostics market in the US. Growing emphasis on preventive care coupled with enhanced access to healthcare facilities would further boost the market growth in the coming years.

With the exponentially rising need for in-vitro diagnostics tools with the growing patient pool, the market players focus on developing advanced diagnostic systems enabling rapid examinations. For instance, in February 2019, Grail, a US-based player in diagnostic services, received financial aid of US$ 1.5 billion from Microsoft and Amazon with an aim to develop new technologies for rapid cancer detection. Additionally, extensive technological advancements due to developed healthcare infrastructure and rising expenditure are generating lucrative opportunities for the growth of the in-vitro diagnostics market in the country. For instance, in July 2019, Sysmex America, Inc., one of the prominent players in the in-vitro diagnostics market, showcased its new integrated in-vitro diagnostic machine named PS-10 at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo organized in Anaheim, California. The machine is designed to perform complex laboratory tests, routine cytometry, and hematology assessments. Similarly, in May 2020, Bio-Rad Laboratories Inc. received Emergency Use Authorization (EUA) for its SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit from the US Food and Drug Administration (FDA). The SARS-CoV-2 ddPCR test runs on Bio-Rad's QX200 and QXDx ddPCR systems.

North America In-Vitro Diagnostics Market Revenue and Forecast to 2030 (US$ Million)

North America In-Vitro Diagnostics Market Segmentation

The North America in-vitro diagnostics market is segmented into product & services, technology, application, end user, and country.

Based on product & services, the North America in-vitro diagnostics market is segmented into reagents & kits, instruments, and software & services. The reagents & kits segment held the largest share of the North America in-vitro diagnostics market in 2022.

Based on technology, the North America in-vitro diagnostics market is segmented into immunoassay/ immunochemistry, clinical chemistry, molecular diagnostics, microbiology, blood glucose self-monitoring, coagulation & hemostasis, hematology, urinalysis, and others. The immunoassay/ immunochemistry segment held the largest share of the North America in-vitro diagnostics market in 2022.

Based on application, the North America in-vitro diagnostics market is segmented into infectious diseases, diabetes, oncology, cardiology, autoimmune diseases, nephrology, and others. The infectious diseases segment held the largest share of the North America in-vitro diagnostics market in 2022.

Based on end user, the North America in-vitro diagnostics market is segmented into hospitals, laboratories, homecare, and others. The hospitals segment held the largest share of the North America in-vitro diagnostics market in 2022.

Based on country, the North America in-vitro diagnostics market is segmented int o the US, Canada, and Mexico. The US dominated the North America in-vitro diagnostics market in 2022.

Abbott Laboratories, Becton Dickinson and Co, bioMerieux SA, Bio-Rad Laboratories Inc, Danaher Corp, F. Hoffmann-La Roche Ltd, Qiagen NV, Siemens AG, Sysmex Corp, and Thermo Fisher Scientific Inc are some of the leading companies operating in the North America in-vitro diagnostics market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America In-Vitro Diagnostics Market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the North America In-Vitro Diagnostics Market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.